Steven Cohen Regenxbio Inc. Transaction History

Point72 Asset Management, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$12.17 - $24.61 $19,472 - $39,376	1,600 New	1,600 $33,000
Q2 2023 Aug 14, 2023	BUY	$17.23 - $21.71 $120 - $151	7 New	7 $0
Q3 2022 Nov 14, 2022	SELL	$22.29 - $35.04 $12.2 Million - $19.2 Million	-549,000 Reduced 96.74%	18,500 $489,000
Q2 2022 Aug 15, 2022	BUY	$19.35 - $35.04 $972,008 - $1.76 Million	50,233 Added 9.71%	567,500 $14 Million
Q1 2022 May 16, 2022	BUY	$24.62 - $34.31 $12.7 Million - $17.7 Million	517,267 New	517,267 $17.2 Million
Q3 2021 Nov 15, 2021	SELL	$29.09 - $45.68 $4.76 Million - $7.47 Million	-163,608 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$32.46 - $40.48 $24.1 Million - $30.1 Million	-742,692 Reduced 81.95%	163,608 $6.36 Million
Q1 2021 May 17, 2021	BUY	$33.61 - $49.95 $26 Million - $38.6 Million	773,100 Added 580.41%	906,300 $30.9 Million
Q4 2020 Feb 16, 2021	BUY	$26.52 - $49.35 $3.53 Million - $6.57 Million	133,200 New	133,200 $6.04 Million
Q3 2020 Nov 16, 2020	SELL	$27.01 - $40.26 $4.96 Million - $7.4 Million	-183,756 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$27.75 - $43.44 $5.1 Million - $7.98 Million	183,756 New	183,756 $6.77 Million

192

43.5M

58.9K

58.4K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $441M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.